MicroRNAs: The Underlying Mediators of Pathogenetic Processes in Vascular Complications of Diabetes

Canadian Journal of Diabetes

Volumn 37, Issue 5, 2013, Pages 339-344

  Ruiz, Michael Anthony ^a   Chakrabarti, Subrata ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Diabetic cardiomyopathy; Diabetic nephropathy; Diabetic retinopathy; MicroRNA; Pathogenesis; Vascular complications of diabetes

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 133A; MICRORNA 146A; MICRORNA 192; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 29; MICRORNA 320; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ZEB1; TRANSCRIPTION FACTOR ZEB2; UNCLASSIFIED DRUG;

DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HEART FAILURE; HUMAN; KIDNEY FAILURE; NONHUMAN; PATHOGENESIS; REVIEW; RNA TRANSLATION; SIGNAL TRANSDUCTION; VISUAL IMPAIRMENT; DIABETIC NEPHROPATHIES; ENDOTHELIUM CELL; FEMALE; FIBROSIS; GENE THERAPY; GENETICS; INSULIN DEPENDENT DIABETES MELLITUS; MALE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; RISK FACTOR; RNA INTERFERENCE;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; ENDOTHELIAL CELLS; FEMALE; FIBROSIS; GENETIC THERAPY; HUMANS; MALE; MICRORNAS; RISK FACTORS; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84884683729     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcjd.2013.07.003     Document Type: Review

References (52)

1. Kolset S.O., Reinholt F.P., Jenssen T. Diabetic nephropathy and extracellular matrix. JHistochem Cytochem 2012, 60:976-986.
2. Chistiakov D.A. Diabetic retinopathy: pathogenic mechanisms and current treatments. Diabetes Metab Syndr 2011, 5:165-172.
3. Goyal B., Mehta A. Diabetic cardiomyopathy: pathophysiological mechanisms and cardiac dysfunction. Hum Exp Toxicol 2013, 32:571-590.
4. Wild S., Roglic G., Green A., et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
5. Bushati N., Cohen S.M. MicroRNA functions. Annu Rev Cell Dev Biol 2007, 23:175-205.
6. Rinn J.L., Chang H.Y. Genome regulation by long noncoding RNAs. Annu Rev Biochem 2012, 81:145-166.
7. Zhang C. MicroRNomics: a newly emerging approach for disease biology. Physiol Genomics 2008, 33:139-147.
8. Kumar M., Nath S., Prasad H.K., et al. MicroRNAs: a new ray of hope for diabetes mellitus. Protein Cell 2012, 3:726-738.
9. Schoof C.R., Botelho E.L., Izzotti A., et al. MicroRNAs in cancer treatment and prognosis. Am J Cancer Res 2012, 2:414-433.
10. Hills C.E., Squires P.E. The role of TGF-β and epithelial-to mesenchymal transition in diabetic nephropathy. Cytokine Growth Factor Rev 2012, 22:131-139.
11. Kato M., Natarajan R. MicroRNA circuits in transforming growth factor-β actions and diabetic nephropathy. Semin Nephrol 2012, 32:253-260.
12. Du B., Ma L.M., Huang M.B., et al. High glucose down-regulates miR-29a to increase collagen IV production in HK-2 cells. FEBS Lett 2010, 584:811-816.
13. Wang B., Komers R., Carew R., et al. Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis. JAm Soc Nephrol 2012, 23:252-265.
14. Kato M., Arce L., Wang M., et al. AmicroRNA circuit mediates transforming growth factor-β1 autoregulation in renal glomerular mesangial cells. Kidney Int 2011, 80:358-368.
15. Putta S., Lanting L., Sun G., et al. Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. JAm Soc Nephrol 2012, 23:458-469.
16. Wang B., Koh P., Winbanks C., et al. miR-200a Prevents renal fibrogenesis through repression of TGF-β2 expression. Diabetes 2011, 60:280-287.
17. Xiong M., Jiang L., Zhou Y., et al. The miR-200 family regulates TGF-β1-induced renal tubular epithelial to mesenchymal transition through Smad pathway by targeting ZEB1 and ZEB2 expression. Am J Physiol Renal Physiol 2012, 302:F369-F379.
18. Gregory P.A., Bert A.G., Paterson E.L., et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008, 10:593-601.
19. Wang B., Herman-Edelstein M., Koh P., et al. E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes 2010, 59:1794-1802.
20. Krupa A., Jenkins R., Luo D.D., et al. Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. JAm Soc Nephrol 2010, 21:438-447.
21. Feng B., Chen S., McArthur K., et al. miR-146a-Mediated extracellular matrix protein production in chronic diabetes complications. Diabetes 2011, 60:2975-2984.
22. Wang Q., Wang Y., Minto A.W., et al. MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J 2008, 22:4126-4135.
23. Long J., Wang Y., Wang W., et al. MicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its invivo knockdown prevents progression of diabetic nephropathy. JBiol Chem 2011, 286:11837-11848.
24. Mu J., Pang Q., Guo Y.H., et al. Functional implications of MicroRNA-215 in TGF-β1-induced phenotypic transition of mesangial cells by targeting CTNNBIP1. PLoS One 2013, 8:e58622.
25. Zhang Z., Luo X., Ding S., et al. MicroRNA-451 regulates p38 MAPK signaling by targeting of Ywhaz and suppresses the mesangial hypertrophy in early diabetic nephropathy. FEBS Lett 2012, 586:20-26.
26. Chen Y.Q., Wang X.X., Yao X.M., et al. MicroRNA-195 promotes apoptosis in mouse podocytes via enhanced caspase activity driven by BCL2 insufficiency. Am J Nephrol 2011, 34:549-559.
27. Li D., Lu Z., Jia J., et al. Changes in microRNAs associated with podocytic adhesion damage under mechanical stress. JRenin Angiotensin Aldosterone Syst 2013, 14:97-102.
28. Long J., Wang Y., Wang W., et al. Identification of microRNA-93 as a novel regulator of vascular endothelial growth factor in hyperglycemic conditions. JBiol Chem 2010, 285:23457-23465.
29. Davidson J.A., Ciulla T.A., McGill J.B., et al. How the diabetic eye loses vision. Endocrine 2007, 32:107-116.
30. Chronopoulos A., Trudeau K., Roy S., et al. High glucose-induced altered basement membrane composition and structure increases trans-endothelial permeability: implications for diabetic retinopathy. Curr Eye Res 2011, 36:747-753.
31. McArthur K., Feng B., Wu Y., et al. MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. Diabetes 2011, 60:1314-1323.
32. Murray A.R., Chen Q., Takahashi Y., et al. MicroRNA-200b downregulates oxidation resistance 1 (Oxr1) expression in the retina of type 1 diabetes model. Invest Ophthalmol Vis Sci 2013, 54:1689-1697.
33. Kovacs B., Lumayag S., Cowan C., et al. MicroRNAs in early diabetic retinopathy in streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci 2011, 52:4402-4409.
34. Feng B., Chakrabarti S. miR-320 Regulates glucose-induced gene expression in diabetes. ISRN Endocrinol 2012, 2012:549875.
35. Bai Y., Bai X., Wang Z., et al. MicroRNA-126 inhibits ischemia-induced retinal neovascularization via regulating angiogenic growth factors. Exp Mol Pathol 2011, 91:471-477.
36. Tomova G.S., Nimbal V., Horwich T.B. Relation between hemoglobin a(1c) and outcomes in heart failure patients with and without diabetes mellitus. Am J Cardiol 2012, 109:1767-1773.
37. Chen S., Evans T., Mukherjee K., et al. Diabetes-induced myocardial structural changes: role of endothelin-1 and its receptors. JMol Cell Cardiol 2000, 32:1621-1629.
38. Feng B., Chen S., George B., et al. miR133a regulates cardiomyocyte hypertrophy in diabetes. Diabetes Metab Res Rev 2010, 26:40-49.
39. Chavali V., Tyagi S.C., Mishra P.K. MicroRNA-133a regulates DNA methylation in diabetic cardiomyocytes. Biochem Biophys Res Commun 2012, 425:668-672.
40. Shan Z.X., Lin Q.X., Deng C.Y., et al. miR-1/miR-206 regulate Hsp60 expression contributing to glucose-mediated apoptosis in cardiomyocytes. FEBS Lett 2010, 584:3592-3600.
41. Katare R., Caporali A., Zentilin L., et al. Intravenous gene therapy with PIM-1 via a cardiotropic viral vector halts the progression of diabetic cardiomyopathy through promotion of prosurvival signaling. Circ Res 2011, 108:1238-1251.
42. Diao X., Shen E., Wang X., et al. Differentially expressed microRNAs and their target genes in the hearts of streptozotocin-induced diabetic mice. Mol Med Rep 2011, 4:633-640.
43. Baseler W.A., Thapa D., Jagannathan R., et al. miR-141 as a regulator of the mitochondrial phosphate carrier (Slc25a3) in the type 1 diabetic heart. Am J Physiol Cell Physiol 2012, 303:C1244-C1251.
44. Shen E., Diao X., Wang X., et al. MicroRNAs involved in the mitogen-activated protein kinase cascades pathway during glucose-induced cardiomyocyte hypertrophy. Am J Pathol 2011, 179:639-650.
45. Feng B., Chen S., Chiu J., et al. Regulation of cardiomyocyte hypertrophy in diabetes at the transcriptional level. Am J Physiol Endocrinol Metab 2008, 294:E1119-E1126.
46. Chen S., Feng B., George B., et al. Transcriptional coactivator p300 regulates glucose-induced gene expression in endothelial cells. Am J Physiol Endocrinol Metab 2010, 298:E127-E137.
47. Greco S., Fasanaro P., Castelvecchio S., et al. MicroRNA dysregulation in diabetic ischemic heart failure patients. Diabetes 2012, 61:1633-1641.
48. Silva V.A., Polesskaya A., Sousa T.A., et al. Expression and cellular localization of microRNA-29b and RAX, an activator of the RNA-dependent protein kinase (PKR), in the retina of streptozotocin-induced diabetic rats. Mol Vis 2011, 17:2228-2240.
49. van Empel V.P., De Windt L.J., da Costa Martins P.A. Circulating miRNAs: reflecting or affecting cardiovascular disease?. Curr Hypertens Rep 2012, 14:498-509.
50. Chironi G.N., Boulanger C.M., Simon A., et al. Endothelial microparticles in diseases. Cell Tissue Res 2009, 335:143-151.
51. Diehl P., Fricke A., Sander L., et al. Microparticles: major transport vehicles for distinct microRNAs in circulation. Cardiovasc Res 2012, 93:633-644.
52. Burger D., Schock S., Thompson C.S., et al. Microparticles: biomarkers and beyond. Clin Sci (Lond) 2013, 124:423-441.